

## Nova Eye Medical FY21 Trading Update

- FY21 unaudited group revenues of \$13.2-\$13.5 million
- Sales revenue for the glaucoma surgical device segment is expected to be \$13.1-\$13.4 million, up 13%-15% (23%-26% in constant currency) on the pcg
- FY21 unaudited group EBITDA loss of \$3.4-\$3.7million, compared to \$5.9 million loss in pcg
- EBITDA for the glaucoma surgical device segment is expected to be approximately \$0.1 million, compared to \$4.1 million loss in pcg


**Adelaide, Australia, 20 July 2021** – Nova Eye Medical Limited (ASX: EYE)(Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices today provided a trading update for the year ended 30 June 2021 (FY21).

Unaudited group revenues are expected to be within the range of \$13.2-\$13.5 million, representing an increase of 4%-6% on the prior corresponding period (pcg). This positive result was driven by solid growth in the glaucoma surgical device segment in the US market coupled with Nova Eye Medical's direct sales model in the German market, despite COVID-impacted trading conditions.

Unaudited FY21 sales revenue for the glaucoma surgical device segment is expected to be \$13.1-\$13.4 million. This compares with sales revenue of \$11.6 million for the year ended 30 June 2020, representing 13%-15% growth in reported revenue. After allowing for the appreciation of the Australia, dollar (A\$) against the US dollar (US\$), sales revenue growth measured in constant currency is expected to be 23%-27%. Approximately 95% of the revenue generated by the glaucoma surgical device segment is denominated in US\$ and the balance is denominated in Euros.

**Table 1: Glaucoma Surgical Devices Revenue (EBITDA in US\$'000's)**

*Note: Sales and EBITDA for FY21 based on mid-point of expected results using FY21 average exchange rates*



Improved operating efficiencies and improved marketing and sales management within the glaucoma surgical device segment resulted in better market penetration and a material reduction in operating costs. Accordingly, the unaudited EBITDA for the glaucoma surgical device segment is expected to be approximately \$0.1 million, compared with a loss of \$4.1 million in the pcg.

The Company's overall unaudited EBITDA loss is expected to be in the range of \$3.4-\$3.7 million, compared to \$5.9 million in pcg. This group loss includes expenditure of approximately \$0.9 million (\$0.1 million in pcg) in relation to the US FDA investigational device exemption (IDE) application for the Company's 2RT<sup>®</sup> treatment for intermediate age-related macular degeneration. 2RT<sup>®</sup> is managed by the Company's AlphaRET division.

Nova Eye Medical expects to release the audited results for the FY21 period in the week beginning 16 August 2021.

***This release dated 20 July 2021 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.***

**– ENDS –**

**Company**

Tom Spurling  
Director  
Nova Eye Medical Limited  
W +61 417 818 658  
[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

**Investors**

Dr. Tom Duthy  
Investor Relations & Corporate Development  
Nova Eye Medical Limited  
W +61 402 493 727  
[tduthy@nova-eye.com](mailto:tduthy@nova-eye.com)

**Media**

Kate Hunt  
Head of Marketing  
Nova Eye Medical Limited  
W +61 404 080 679  
[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

---

**ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack<sup>™</sup> minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3<sup>®</sup> glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales

---

headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: [www.nova-eye.com](http://www.nova-eye.com)